Retatrutide, from Soma Pharmaceuticals , is gaining considerable attention as a potential treatment for obesity regulation. This unique drug integrates the activity of a GLP-1 receptor agonist and a GIP receptor activator , aiming to effectively promote reduced body fat but also target associated metabolic conditions . Initial patient trials have d